http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 11 Jun 2026 09:02:05 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/NeuroSense+receives+South+Korean+patent+for+ALS+drug+PrimeC/26633451.html <p>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced that the Korean Intellectual Property Office has issued Korean Patent Number 10-2969898 covering the composition of PrimeC, the company's drug candidate for treating amyotrophic lateral sclerosis.</p><p>The patent covers PrimeC's tablet formulation, manufacturing process, pharmacokinetic characteristics, and pharmaceutical use for ALS treatment. Patent protection in South Korea is expected to extend through 2042.</p><p>"This patent grant further strengthens our growing global intellectual property estate surrounding PrimeC," said Alon Ben-Noon, Chief Executive Officer of NeuroSense. "South Korea is an important pharmaceutical market, and this milestone reflects the continued recognition of the novelty and proprietary nature of PrimeC http://www.streetinsider.com/Corporate+News/NeuroSense+receives+South+Korean+patent+for+ALS+drug+PrimeC/26633451.html Thu, 11 Jun 2026 09:02:05 -0400 H1Z NRSN NRSNW http://www.streetinsider.com/Corporate+News/NeuroSense+receives+South+Korean+patent+for+ALS+drug+PrimeC/26633451.html <p>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced that the Korean Intellectual Property Office has issued Korean Patent Number 10-2969898 covering the composition of PrimeC, the company's drug candidate for treating amyotrophic lateral sclerosis.</p><p>The patent covers PrimeC's tablet formulation, manufacturing process, pharmacokinetic characteristics, and pharmaceutical use for ALS treatment. Patent protection in South Korea is expected to extend through 2042.</p><p>"This patent grant further strengthens our growing global intellectual property estate surrounding PrimeC," said Alon Ben-Noon, Chief Executive Officer of NeuroSense. "South Korea is an important pharmaceutical market, and this milestone reflects the continued recognition of the novelty and proprietary nature of PrimeC http://www.streetinsider.com/Corporate+News/NeuroSense+receives+South+Korean+patent+for+ALS+drug+PrimeC/26633451.html Thu, 11 Jun 2026 09:02:05 -0400 H1Z NRSN NRSNW http://www.streetinsider.com/Corporate+News/NeuroSense+receives+South+Korean+patent+for+ALS+drug+PrimeC/26633451.html <p>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced that the Korean Intellectual Property Office has issued Korean Patent Number 10-2969898 covering the composition of PrimeC, the company's drug candidate for treating amyotrophic lateral sclerosis.</p><p>The patent covers PrimeC's tablet formulation, manufacturing process, pharmacokinetic characteristics, and pharmaceutical use for ALS treatment. Patent protection in South Korea is expected to extend through 2042.</p><p>"This patent grant further strengthens our growing global intellectual property estate surrounding PrimeC," said Alon Ben-Noon, Chief Executive Officer of NeuroSense. "South Korea is an important pharmaceutical market, and this milestone reflects the continued recognition of the novelty and proprietary nature of PrimeC http://www.streetinsider.com/Corporate+News/NeuroSense+receives+South+Korean+patent+for+ALS+drug+PrimeC/26633451.html Thu, 11 Jun 2026 09:02:05 -0400 H1Z NRSN NRSNW http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Jun+11/26633367.html si-local-file:///var/storage/secattach/20260611/26633367.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Jun+11/26633367.html Thu, 11 Jun 2026 09:00:00 -0400 NRSN O.31364977 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Jun+11/26633367.html si-local-file:///var/storage/secattach/20260611/26633367.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Jun+11/26633367.html Thu, 11 Jun 2026 09:00:00 -0400 NRSN O.31364977 http://www.streetinsider.com/Press+Releases/NeuroSense+Granted+South+Korean+Patent+Covering+PrimeC+Composition+for+ALS/26633409.html <div class="xn-content"> <ul type="disc"><li><i>Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS</i></li><li><i>Expands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>, <location value="LC/br" idsrc="xmltag.org" >Brazil</location>, <location value="LC/au" idsrc="xmltag.org" >Australia</location> and <location value="LC/us" idsrc="xmltag.org" >the United States</location></i></li><li><i>Further strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeC</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"  or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, http://www.streetinsider.com/Press+Releases/NeuroSense+Granted+South+Korean+Patent+Covering+PrimeC+Composition+for+ALS/26633409.html Thu, 11 Jun 2026 09:00:00 -0400 A.06822034 H1Z NRSN NRSNW O.20026344 O.31364977 http://www.streetinsider.com/Press+Releases/NeuroSense+Granted+South+Korean+Patent+Covering+PrimeC+Composition+for+ALS/26633409.html <div class="xn-content"> <ul type="disc"><li><i>Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS</i></li><li><i>Expands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>, <location value="LC/br" idsrc="xmltag.org" >Brazil</location>, <location value="LC/au" idsrc="xmltag.org" >Australia</location> and <location value="LC/us" idsrc="xmltag.org" >the United States</location></i></li><li><i>Further strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeC</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"  or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, http://www.streetinsider.com/Press+Releases/NeuroSense+Granted+South+Korean+Patent+Covering+PrimeC+Composition+for+ALS/26633409.html Thu, 11 Jun 2026 09:00:00 -0400 A.06822034 H1Z NRSN NRSNW O.20026344 O.31364977 http://www.streetinsider.com/Press+Releases/NeuroSense+Granted+South+Korean+Patent+Covering+PrimeC+Composition+for+ALS/26633409.html <div class="xn-content"> <ul type="disc"><li><i>Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS</i></li><li><i>Expands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>, <location value="LC/br" idsrc="xmltag.org" >Brazil</location>, <location value="LC/au" idsrc="xmltag.org" >Australia</location> and <location value="LC/us" idsrc="xmltag.org" >the United States</location></i></li><li><i>Further strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeC</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"  or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, http://www.streetinsider.com/Press+Releases/NeuroSense+Granted+South+Korean+Patent+Covering+PrimeC+Composition+for+ALS/26633409.html Thu, 11 Jun 2026 09:00:00 -0400 A.06822034 H1Z NRSN NRSNW O.20026344 O.31364977 http://www.streetinsider.com/Press+Releases/NeuroSense+Granted+South+Korean+Patent+Covering+PrimeC+Composition+for+ALS/26633409.html <div class="xn-content"> <ul type="disc"><li><i>Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS</i></li><li><i>Expands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>, <location value="LC/br" idsrc="xmltag.org" >Brazil</location>, <location value="LC/au" idsrc="xmltag.org" >Australia</location> and <location value="LC/us" idsrc="xmltag.org" >the United States</location></i></li><li><i>Further strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeC</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"  or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, http://www.streetinsider.com/Press+Releases/NeuroSense+Granted+South+Korean+Patent+Covering+PrimeC+Composition+for+ALS/26633409.html Thu, 11 Jun 2026 09:00:00 -0400 A.06822034 H1Z NRSN NRSNW O.20026344 O.31364977 http://www.streetinsider.com/Press+Releases/NeuroSense+Granted+South+Korean+Patent+Covering+PrimeC+Composition+for+ALS/26633409.html <div class="xn-content"> <ul type="disc"><li><i>Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS</i></li><li><i>Expands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>, <location value="LC/br" idsrc="xmltag.org" >Brazil</location>, <location value="LC/au" idsrc="xmltag.org" >Australia</location> and <location value="LC/us" idsrc="xmltag.org" >the United States</location></i></li><li><i>Further strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeC</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"  or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, http://www.streetinsider.com/Press+Releases/NeuroSense+Granted+South+Korean+Patent+Covering+PrimeC+Composition+for+ALS/26633409.html Thu, 11 Jun 2026 09:00:00 -0400 A.06822034 H1Z NRSN NRSNW O.20026344 O.31364977 http://www.streetinsider.com/Press+Releases/NeuroSense+Granted+South+Korean+Patent+Covering+PrimeC+Composition+for+ALS/26633409.html <div class="xn-content"> <ul type="disc"><li><i>Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS</i></li><li><i>Expands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>, <location value="LC/br" idsrc="xmltag.org" >Brazil</location>, <location value="LC/au" idsrc="xmltag.org" >Australia</location> and <location value="LC/us" idsrc="xmltag.org" >the United States</location></i></li><li><i>Further strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeC</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"  or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, http://www.streetinsider.com/Press+Releases/NeuroSense+Granted+South+Korean+Patent+Covering+PrimeC+Composition+for+ALS/26633409.html Thu, 11 Jun 2026 09:00:00 -0400 A.06822034 H1Z NRSN NRSNW O.20026344 O.31364977 http://www.streetinsider.com/PRNewswire/NeuroSense+Granted+South+Korean+Patent+Covering+PrimeC+Composition+for+ALS/26633409.html <div class="xn-content"> <ul type="disc"><li><i>Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS</i></li><li><i>Expands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>, <location value="LC/br" idsrc="xmltag.org" >Brazil</location>, <location value="LC/au" idsrc="xmltag.org" >Australia</location> and <location value="LC/us" idsrc="xmltag.org" >the United States</location></i></li><li><i>Further strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeC</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"  or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, http://www.streetinsider.com/PRNewswire/NeuroSense+Granted+South+Korean+Patent+Covering+PrimeC+Composition+for+ALS/26633409.html Thu, 11 Jun 2026 09:00:00 -0400 A.06822034 H1Z NRSN NRSNW O.20026344 O.31364977 http://www.streetinsider.com/PRNewswire/NeuroSense+Granted+South+Korean+Patent+Covering+PrimeC+Composition+for+ALS/26633409.html <div class="xn-content"> <ul type="disc"><li><i>Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS</i></li><li><i>Expands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>, <location value="LC/br" idsrc="xmltag.org" >Brazil</location>, <location value="LC/au" idsrc="xmltag.org" >Australia</location> and <location value="LC/us" idsrc="xmltag.org" >the United States</location></i></li><li><i>Further strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeC</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"  or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, http://www.streetinsider.com/PRNewswire/NeuroSense+Granted+South+Korean+Patent+Covering+PrimeC+Composition+for+ALS/26633409.html Thu, 11 Jun 2026 09:00:00 -0400 A.06822034 H1Z NRSN NRSNW O.20026344 O.31364977 http://www.streetinsider.com/PRNewswire/NeuroSense+Granted+South+Korean+Patent+Covering+PrimeC+Composition+for+ALS/26633409.html <div class="xn-content"> <ul type="disc"><li><i>Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS</i></li><li><i>Expands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>, <location value="LC/br" idsrc="xmltag.org" >Brazil</location>, <location value="LC/au" idsrc="xmltag.org" >Australia</location> and <location value="LC/us" idsrc="xmltag.org" >the United States</location></i></li><li><i>Further strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeC</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"  or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, http://www.streetinsider.com/PRNewswire/NeuroSense+Granted+South+Korean+Patent+Covering+PrimeC+Composition+for+ALS/26633409.html Thu, 11 Jun 2026 09:00:00 -0400 A.06822034 H1Z NRSN NRSNW O.20026344 O.31364977 http://www.streetinsider.com/PRNewswire/NeuroSense+Granted+South+Korean+Patent+Covering+PrimeC+Composition+for+ALS/26633409.html <div class="xn-content"> <ul type="disc"><li><i>Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS</i></li><li><i>Expands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>, <location value="LC/br" idsrc="xmltag.org" >Brazil</location>, <location value="LC/au" idsrc="xmltag.org" >Australia</location> and <location value="LC/us" idsrc="xmltag.org" >the United States</location></i></li><li><i>Further strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeC</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"  or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, http://www.streetinsider.com/PRNewswire/NeuroSense+Granted+South+Korean+Patent+Covering+PrimeC+Composition+for+ALS/26633409.html Thu, 11 Jun 2026 09:00:00 -0400 A.06822034 H1Z NRSN NRSNW O.20026344 O.31364977 http://www.streetinsider.com/PRNewswire/NeuroSense+Granted+South+Korean+Patent+Covering+PrimeC+Composition+for+ALS/26633409.html <div class="xn-content"> <ul type="disc"><li><i>Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS</i></li><li><i>Expands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>, <location value="LC/br" idsrc="xmltag.org" >Brazil</location>, <location value="LC/au" idsrc="xmltag.org" >Australia</location> and <location value="LC/us" idsrc="xmltag.org" >the United States</location></i></li><li><i>Further strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeC</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"  or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, http://www.streetinsider.com/PRNewswire/NeuroSense+Granted+South+Korean+Patent+Covering+PrimeC+Composition+for+ALS/26633409.html Thu, 11 Jun 2026 09:00:00 -0400 A.06822034 H1Z NRSN NRSNW O.20026344 O.31364977 http://www.streetinsider.com/PRNewswire/NeuroSense+Granted+South+Korean+Patent+Covering+PrimeC+Composition+for+ALS/26633409.html <div class="xn-content"> <ul type="disc"><li><i>Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS</i></li><li><i>Expands intellectual property protection in one of the world's leading pharmaceutical markets, following recent patent advancements in <location value="LC/jp" idsrc="xmltag.org" >Japan</location>, <location value="LC/br" idsrc="xmltag.org" >Brazil</location>, <location value="LC/au" idsrc="xmltag.org" >Australia</location> and <location value="LC/us" idsrc="xmltag.org" >the United States</location></i></li><li><i>Further strengthens global patent portfolio as NeuroSense prepares to initiate Phase 3 development of PrimeC</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense"  or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, http://www.streetinsider.com/PRNewswire/NeuroSense+Granted+South+Korean+Patent+Covering+PrimeC+Composition+for+ALS/26633409.html Thu, 11 Jun 2026 09:00:00 -0400 A.06822034 H1Z NRSN NRSNW O.20026344 O.31364977 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Jun+09/26621986.html si-local-file:///var/storage/secattach/20260609/26621986.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Jun+09/26621986.html Tue, 09 Jun 2026 10:14:00 -0400 NRSN O.31364977 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Jun+09/26621986.html si-local-file:///var/storage/secattach/20260609/26621986.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++NeuroSense+Therapeutics+++For%3A+Jun+09/26621986.html Tue, 09 Jun 2026 10:14:00 -0400 NRSN O.31364977 http://www.streetinsider.com/Corporate+News/NeuroSense+receives+Japanese+patent+for+ALS+drug+candidate+PrimeC/26621396.html <p>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced that the Japan Patent Office has issued Japanese Patent 7857044 covering the company's lead drug candidate PrimeC for treating amyotrophic lateral sclerosis.</p><p>The patent, titled "Compositions comprising ciprofloxacin and celecoxib," includes 17 claims and provides protection through 2042 for PrimeC's formulation and manufacturing process. The patent covers the synchronized delivery profile of celecoxib and ciprofloxacin, which targets multiple mechanisms underlying ALS progression.</p><p>"This patent grant further strengthens our global intellectual property estate around PrimeC and reinforces the novelty of our synchronized extended-release formulation," said Alon Ben-Noon, Chief Executive Officer of NeuroSense. "Japan is a key pharmaceutical http://www.streetinsider.com/Corporate+News/NeuroSense+receives+Japanese+patent+for+ALS+drug+candidate+PrimeC/26621396.html Tue, 09 Jun 2026 09:01:43 -0400 H1Z NRSN NRSNW http://www.streetinsider.com/Corporate+News/NeuroSense+receives+Japanese+patent+for+ALS+drug+candidate+PrimeC/26621396.html <p>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced that the Japan Patent Office has issued Japanese Patent 7857044 covering the company's lead drug candidate PrimeC for treating amyotrophic lateral sclerosis.</p><p>The patent, titled "Compositions comprising ciprofloxacin and celecoxib," includes 17 claims and provides protection through 2042 for PrimeC's formulation and manufacturing process. The patent covers the synchronized delivery profile of celecoxib and ciprofloxacin, which targets multiple mechanisms underlying ALS progression.</p><p>"This patent grant further strengthens our global intellectual property estate around PrimeC and reinforces the novelty of our synchronized extended-release formulation," said Alon Ben-Noon, Chief Executive Officer of NeuroSense. "Japan is a key pharmaceutical http://www.streetinsider.com/Corporate+News/NeuroSense+receives+Japanese+patent+for+ALS+drug+candidate+PrimeC/26621396.html Tue, 09 Jun 2026 09:01:43 -0400 H1Z NRSN NRSNW http://www.streetinsider.com/Corporate+News/NeuroSense+receives+Japanese+patent+for+ALS+drug+candidate+PrimeC/26621396.html <p>NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced that the Japan Patent Office has issued Japanese Patent 7857044 covering the company's lead drug candidate PrimeC for treating amyotrophic lateral sclerosis.</p><p>The patent, titled "Compositions comprising ciprofloxacin and celecoxib," includes 17 claims and provides protection through 2042 for PrimeC's formulation and manufacturing process. The patent covers the synchronized delivery profile of celecoxib and ciprofloxacin, which targets multiple mechanisms underlying ALS progression.</p><p>"This patent grant further strengthens our global intellectual property estate around PrimeC and reinforces the novelty of our synchronized extended-release formulation," said Alon Ben-Noon, Chief Executive Officer of NeuroSense. "Japan is a key pharmaceutical http://www.streetinsider.com/Corporate+News/NeuroSense+receives+Japanese+patent+for+ALS+drug+candidate+PrimeC/26621396.html Tue, 09 Jun 2026 09:01:43 -0400 H1Z NRSN NRSNW http://www.streetinsider.com/Press+Releases/NeuroSense+Therapeutics+Receives+Japanese+Patent+Grant+for+PrimeC+Novel+Composition/26621322.html <div class="xn-content"> <p class="prntac"><i>Patent Protection Extends Through 2042 following recent <location value="LC/us" idsrc="xmltag.org" >U.S</location>., <location value="LC/au" idsrc="xmltag.org" >Australia</location> and <location value="LC/br" idsrc="xmltag.org" >Brazil</location> patents</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Japan Patent Office has issued a Japanese Patent 7857044 covering the Company's lead drug candidate for the treatment of amyotrophic lateral sclerosis (ALS).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/NeuroSense+Therapeutics+Receives+Japanese+Patent+Grant+for+PrimeC+Novel+Composition/26621322.html Tue, 09 Jun 2026 09:00:00 -0400 A.06822034 H1Z NRSN NRSNW O.20026344 O.31364977 http://www.streetinsider.com/Press+Releases/NeuroSense+Therapeutics+Receives+Japanese+Patent+Grant+for+PrimeC+Novel+Composition/26621322.html <div class="xn-content"> <p class="prntac"><i>Patent Protection Extends Through 2042 following recent <location value="LC/us" idsrc="xmltag.org" >U.S</location>., <location value="LC/au" idsrc="xmltag.org" >Australia</location> and <location value="LC/br" idsrc="xmltag.org" >Brazil</location> patents</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Japan Patent Office has issued a Japanese Patent 7857044 covering the Company's lead drug candidate for the treatment of amyotrophic lateral sclerosis (ALS).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/NeuroSense+Therapeutics+Receives+Japanese+Patent+Grant+for+PrimeC+Novel+Composition/26621322.html Tue, 09 Jun 2026 09:00:00 -0400 A.06822034 H1Z NRSN NRSNW O.20026344 O.31364977 http://www.streetinsider.com/Press+Releases/NeuroSense+Therapeutics+Receives+Japanese+Patent+Grant+for+PrimeC+Novel+Composition/26621322.html <div class="xn-content"> <p class="prntac"><i>Patent Protection Extends Through 2042 following recent <location value="LC/us" idsrc="xmltag.org" >U.S</location>., <location value="LC/au" idsrc="xmltag.org" >Australia</location> and <location value="LC/br" idsrc="xmltag.org" >Brazil</location> patents</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location></span>, <span class="legendSpanClass"><chron>June 9, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.neurosense-tx.com/" target="_blank" rel="nofollow"><span value="NASDAQ-NMS:NRSN" idsrc="xmltag.org" >NeuroSense Therapeutics Ltd.</span></a> (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Japan Patent Office has issued a Japanese Patent 7857044 covering the Company's lead drug candidate for the treatment of amyotrophic lateral sclerosis (ALS).</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/NeuroSense+Therapeutics+Receives+Japanese+Patent+Grant+for+PrimeC+Novel+Composition/26621322.html Tue, 09 Jun 2026 09:00:00 -0400 A.06822034 H1Z NRSN NRSNW O.20026344 O.31364977